Allegro reported that its investigational nanotechnology Hydrocelin produced statistically significant improvements in pain and function over six months in a 30-patient study of knee osteoarthritis.
Patients assessed using the 100-point KOOS score showed median improvements of 21.7 points at four weeks, 31.1 points at 12 weeks and 35.7 points at six months, figures the company presented as statistically significant compared with baseline. Investigators observed a rapid onset of benefit, with most patients experiencing meaningful improvement within the first week, and only one minor adverse event of injection-site pain that resolved within 24 hours.
The company claims Hydrocelin is a first-in-class injectable nanotechnology intended to restore the joint’s shock-absorbing properties through cross-linked microparticles that disperse in synovial fluid.
Allegro also completed recruitment ahead of schedule in a European feasibility trial, with the last patient treated in Belgium, and says three-month and topline data are expected in the second half of 2026 to inform a registrational study.
